Piretanide: Difference between revisions
No edit summary |
m (Protected "Piretanide": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))) |
(No difference)
|
Latest revision as of 16:57, 20 August 2015
Clinical data | |
---|---|
Trade names | Arelix, Eurelix, Tauliz |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
KEGG | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C17H18N2O5S |
Molar mass | 362.40 g/mol |
3D model (JSmol) | |
| |
(verify) |
WikiDoc Resources for Piretanide |
Articles |
---|
Most recent articles on Piretanide |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Piretanide at Clinical Trials.gov Clinical Trials on Piretanide at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Piretanide
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Piretanide Discussion groups on Piretanide Patient Handouts on Piretanide Directions to Hospitals Treating Piretanide Risk calculators and risk factors for Piretanide
|
Healthcare Provider Resources |
Causes & Risk Factors for Piretanide |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Piretanide (INN, trade names Arelix, Eurelix, Tauliz) has been synthesized in 1973 at Hoechst AG (Germany) as a loop diuretic compound by using a then-new method for introducing cyclic amine residues in an aromatic nucleus in the presence of other aromatically bonded functional groups. Studies of piretanide in rats and dogs in comparison with other high-ceiling diuretics such as furosemide and bumetanide found a more suitable dose/response rate (regression line) and a more favourable sodium/potassium excretion ratio. These findings led eventually to clinical studies in man and finally to the introduction as a saluretic and antihypertensive[1] medication in Germany, France, Italy and other countries.
References
- ↑ Haberfeld, H, ed. (2009). Austria-Codex (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 3-85200-196-X.
- W.Merkel, D.Bormann, D.Mania, R.Muschaweck and M.Hropot, Eur. J. Med. Chem.-Chim.Ther. 11,399 (1976).
- W.Merkel, D.Mania and D.Bormann, Liebigs Ann. Chem. 461 (1979).
- Pages with script errors
- CS1 maint: Unrecognized language
- Template:drugs.com link with non-standard subpage
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Diuretics
- Cardiovascular Drugs
- Drug